for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mallinckrodt PLC

MNK.N

Latest Trade

2.86USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.43

 - 

32.34

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2.86
Open
--
Volume
--
3M AVG Volume
208.68
Today's High
--
Today's Low
--
52 Week High
32.34
52 Week Low
1.43
Shares Out (MIL)
84.01
Market Cap (MIL)
240.26
Forward P/E
0.34
Dividend (Yield %)
--

Next Event

Q3 2019 Mallinckrodt Plc Earnings Release

Latest Developments

More

Armistice Capital Reports 8.5% Passive Stake In Mallinckrodt As Of Oct. 2

Mallinckrodt Announces Positive data for Acthar Gel in Multiple Sclerosis Relapse Patients

Mallinckrodt Announces Positive Top-Line Results From Pivotal Phase 3 Clinical Trial Of Stratagraft Regenerative Tissue In Patients With Deep Partial-Thickness Thermal Burns

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mallinckrodt PLC

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Industry

Major Drugs

Contact Info

3 Lotus Park, The Causeway

+44.1784.636700

http://mallinckrodt.com

Executive Leadership

Angus Charles Russell

Independent Non-Executive Chairman of the Board

Mark C. Trudeau

President, Chief Executive Officer, Director

Bryan M. Reasons

Chief Financial Officer

Frank G. Scholz

Executive Vice President and Chief Operations and Digital Innovation Officer

Ian J. Watkins

Chief Human Resource Officer

Key Stats

3.08 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

3.4K

2017

3.2K

2018

3.2K

2019(E)

3.2K
EPS (USD)

2016

7.790

2017

7.490

2018

8.010

2019(E)

8.490
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.07
Price To Book (MRQ)
0.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
180.18
LT Debt To Equity (MRQ)
156.84
Return on Investment (TTM)
-30.29
Return on Equity (TTM)
-27.37

Latest News

Latest News

UPDATE 1-Drugmakers look to use Purdue Pharma's bankruptcy to settle U.S. opioid suits -WSJ

Endo International Plc, Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP's bankruptcy, the Wall Street Journal reported, citing internal documents and a person...

Mallinckrodt sells unit for up to $250 million, sees path forward to settle opioid lawsuits

Mallinckrodt Plc <MNK.N> shares surged more than 50% on Tuesday after it agreed to sell its contract manufacturing unit to reduce debt and its chief executive officer raised hopes that the company could reach a global settlement to resolve all opioid litigation.

Mallinckrodt to sell unit BioVectra for up to $250 mln

Drugmaker Mallinckrodt Plc said on Tuesday it would sell its unit BioVectra Inc to private equity firm H.I.G. Capital for up to $250 million.

Mallinckrodt to pay $24 million in cash to settle opioid lawsuits with two Ohio counties

Mallinckrodt plc said on Friday it had agreed to pay $24 million in cash to two counties in Ohio, to settle lawsuits related to an ongoing multidistrict opioid litigation in the United States.

Mallinckrodt to pay $24 mln in cash to settle opioid lawsuits with two Ohio counties

Drugmaker Mallinckrodt plc said on Friday it will pay $24 million in cash to two counties in Ohio, to settle lawsuits in connection with an ongoing multidistrict opioid litigation in the United States.

Mallinckrodt downplays bankruptcy fears, says hires advisers 'all the time'

Mallinckrodt Plc on Thursday downplayed a media report that the company had hired restructuring firms and may choose to seek bankruptcy protection.

Mallinckrodt taps restructuring firms: Bloomberg

Mallinckrodt Plc <MNK.N> has hired restructuring firms and may choose to seek bankruptcy protection, Bloomberg reported on Wednesday, sending the drugmaker's shares down 40% in after-hours trading.

Drugmaker Mallinckrodt's shares fall 12% after unfavorable patent ruling

Shares of Mallinckrodt Plc <MNK.N> fell 12% on Tuesday after a U.S. Court of Appeals upheld a federal district court's decision to reject the drugmaker's patent infringement lawsuit against Praxair Inc's nitric oxide drug product delivery system.

IN BRIEF: Federal prosecutors seek more records from opioid maker Mallinckrodt

Mallinckrodt PLC, one of the largest U.S. manufacturers of prescription opioids, says federal prosecutors in Brooklyn investigating the company recently sought records regarding its program to prevent the diversion of drugs for illicit purposes.

Mallinckrodt shares fall on Acthar worries, generics spinoff suspension

Mallinckrodt Plc <MNK.N> suspended plans to spin off its specialty generics unit, citing opioid litigation uncertainties, and warned Acthar gel revenue was unlikely to exceed $1 billion this year, sending its shares down about 15% on Tuesday.

Mallinckrodt suspends plans to spin off generics unit

Mallinckrodt Plc said on Tuesday it has suspended plans to spin off its specialty generics business, citing uncertainties tied to the opioid litigation and current market conditions.

Mallinckrodt must face investors' antitrust lawsuit over expensive medication

Mallinckrodt PLC must face a proposed class action lawsuit alleging it failed to disclose an imminent $100 million Federal Trade Commission settlement resolving claims it illegally maintained a monopoly over an expensive drug, a federal judge has ruled.

U.S. says Mallinckrodt owes bigger rebates after massive price hike

The federal government has urged a judge to prevent Mallinckrodt PLC from ducking payment of hundreds of millions of dollars in rebates to state Medicaid programs to account for a "massive price hike" for the drugmaker's top-selling medication.

Mallinckrodt to settle U.S. drug marketing probe, fight kickback case

Mallinckrodt Plc on Wednesday said it had tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker it now owns marketed an expensive treatment for a rare infant seizure disorder and multiple sclerosis.

Mallinckrodt expects to pay DoJ $15.4 mln over Questcor investigation

Mallinckrodt Plc said on Wednesday it reached an agreement with the U.S. Department of Justice to resolve a government investigation into its subsidiary Questcor and expects to pay $15.4 million.

Mallinckrodt's Amitiza to stay with branded business after spin-off

Mallinckrodt Plc said on Tuesday it would spin off its generic drugs business as a separate unit and keep constipation medicine Amitiza as part of its specialty branded drugs business, which will be renamed as Sonorant Therapeutics Plc.

Mallinckrodt to spin-off generics business, keep constipation drug

Mallinckrodt Plc said on Tuesday it would spin-off its specialty generics unit and rename the remaining specialty branded drugs business to Sonorant Therapeutics Plc.

Mallinckrodt sues U.S. health agencies, sees 10% hit to Acthar gel sales

Mallinckrodt Plc filed a lawsuit against the U.S. Department of Health and Human Services and forecast an about 10% hit to annual net sales of Acthar gel following changes to Medicaid rebate calculations, sending its shares plunging as much as 34% on Tuesday.

Mallinckrodt sues U.S. health agencies, sees 10% hit to MS treatment sales

Mallinckrodt Plc filed a lawsuit against the U.S. Department of Health and Human Services and forecast an about 10% hit to annual net sales of its gel used to treat multiple sclerosis symptoms following changes to Medicaid rebate calculations, sending shares plunging as...

Federal prosecutors in Brooklyn subpoena opioid maker Mallinckrodt

Mallinckrodt PLC, one of the largest U.S. manufacturers of prescription opioids, said it has received a grand jury subpoena from federal prosecutors in Brooklyn seeking records related to its marketing and sale of controlled substances.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up